Our Aim
Advancing Innovative Gene Therapy
Our Aim
- Objective: Develop an innovative gene therapy platform for cardiovascular disease (CVD), focusing on coronary heart disease (CHD) and heart failure (HF).
- CHD: Build-up of plaque in heart arteries leading to heart attack or chronic ischemic cardiomyopathy.
- HF: Inability of the heart muscle to pump sufficiently, resulting from CHD.
- Need for effective and safe treatments for CHD and HF.
- Emerging insights on the potential of non-coding RNA (ncRNA) for treating CVDs.
- Challenges in delivery of RNA-based therapeutics in clinical studies.
- Validation of innovative cardiac-targeted vector technologies in preclinical models of CHD and HF.
- Scalable manufacturing process for cardiac-targeted vectors under GMP conditions.
- Early engagement with the European Medicines Agency for regulatory advice.
- Simultaneous development and preclinical validation of multiple promising leads.
- Establishing a contingency strategy and fueling a pipeline of novel therapies.
- Involvement of commercial stakeholders and partner SMEs to maximize project impact.
- Strengthening the EU's position in the advanced therapy medicinal products (ATMPs) field.
- Improving perspectives for treating patients with CVD.
Our Approach
